SEARCH

SEARCH BY CITATION

References

  • Abdelmalik P. A., Shannon P., Yiu A., Liang P., Adamchik Y., Weisspapir M., Samoilova M., Burnham W. M. and Carlen P. L. (2007) Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction. Neurobiol. Dis. 26, 646660.
  • Abeti R., Abramov A. Y. and Duchen M. R. (2011) Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134, 16581672.
  • Abramov A. Y., Canevari L. and Duchen M. R. (2004) Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24, 565575.
  • Amatniek J. C., Hauser W. A., DelCastillo-Castaneda C., Jacobs D. M., Marder K., Bell K., Albert M., Brandt J. and Stern Y. (2006) Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47, 867872.
  • Ashe K. H. and Zahs K. R. (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66, 631645.
  • Avila J., Wandosell F. and Hernandez F. (2010) Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev. Neurother. 10, 703710.
  • Bakker A., Krauss G. L., Albert M. S., Speck C. L., Jones L. R., Stark C. E., Yassa M. A., Bassett S. S., Shelton A. L. and Gallagher M. (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74, 467474.
  • Bigl M. and Eschrich K. (1995) Interaction of rat brain phosphofructokinase with Alzheimer's beta A4-amyloid. Neurochem. Int. 26, 6975.
  • Blass J. P. (2001) Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J. Neurosci. Res. 66, 851856.
  • Brown A. M. and Ransom B. R. (2007) Astrocyte glycogen and brain energy metabolism. Glia 55, 12631271.
  • Busche M. A., Chen X., Henning H. A., Reichwald J., Staufenbiel M., Sakmann B. and Konnerth A. (2012) Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 109, 87408745.
  • Casley C. S., Canevari L., Land J. M., Clark J. B. and Sharpe M. A. (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80, 91100.
  • Choi I. Y. and Gruetter R. (2003) In vivo 13C NMR assessment of brain glycogen concentration and turnover in the awake rat. Neurochem. Int. 43, 317322.
  • Cohen I., Navarro V., Clemenceau S., Baulac M. and Miles R. (2002) On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 298, 14181421.
  • Cuevas M. E., Haensgen H., Sepulveda F. J., Zegers G., Roa J., Opazo C. and Aguayo L. G. (2011) Soluble Abeta1-40 peptide increases excitatory neurotransmission and induces epileptiform activity in hippocampal neurons. J. Alzheimers Dis. 23, 673687.
  • Cunnane S., Nugent S., Roy M., et al. (2011) Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27, 320.
  • de la Torre J. C. (2008) Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener. Dis. 5, 126132.
  • Dickerson B. C., Salat D. H., Greve D. N., et al. (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404411.
  • Dienel G. A. and Cruz N. F. (2006) Astrocyte activation in working brain: energy supplied by minor substrates. Neurochem. Int. 48, 586595.
  • Egras A. M., Hamilton W. R., Lenz T. L. and Monaghan M. S. (2011) An evidence-based review of fat modifying supplemental weight loss products. J. Obes. 2011, 17.
  • Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Langstrom B. and Nordberg A. (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 28562866.
  • Filippini N., MacIntosh B. J., Hough M. G., Goodwin G. M., Frisoni G. B., Smith S. M., Matthews P. M., Beckmann C. F. and Mackay C. E. (2009) Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. USA 106, 72097214.
  • Frackowiak R. S., Pozzilli C., Legg N. J., Du Boulay G. H., Marshall J., Lenzi G. L. and Jones T. (1981) Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104, 753778.
  • Garcia-Alloza M., Robbins E. M., Zhang-Nunes S. X., Purcell S. M., Betensky R. A., Raju S., Prada C., Greenberg S. M., Bacskai B. J. and Frosch M. P. (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516524.
  • Guglielmotto M., Aragno M., Autelli R., et al. (2009a) The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem. 108, 10451056.
  • Guglielmotto M., Tamagno E. and Danni O. (2009b) Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: two sides of the same coin. Scientific World J. 9, 781791.
  • Hardy J. (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110, 11291134.
  • Hauptmann S., Scherping I., Drose S., Brandt U., Schulz K. L., Jendrach M., Leuner K., Eckert A. and Muller W. E. (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 30, 15741586.
  • Henderson S. T. (2008) Ketone bodies as a therapeutic for Alzheimer's disease. NeuroTherapeutics 5, 470480.
  • Henderson S. T., Vogel J. L., Barr L. J., Garvin F., Jones J. J. and Costantini L. C. (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. 6, 31.
  • Holmgren C. D., Mukhtarov M., Malkov A. E., Popova I. Y., Bregestovski P. and Zilberter Y. (2010) Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro. J. Neurochem. 112, 900912.
  • Hong W. K., Han E. H., Kim D. G., Ahn J. Y., Park J. S. and Han B. G. (2007) Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. Neurochem. Res. 32, 14831488.
  • Hoyer S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115125.
  • Huang Y. and Mucke L. (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 12041222.
  • Ivanov A., Mukhtarov M., Bregestovski P. and Zilberter Y. (2011) Lactate effectively covers energy demands during neuronal network activity in neonatal hippocampal slices. Front. Neuroenergetics 3, 114.
  • Jankowsky J. L., Fadale D. J., Anderson J., et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159170.
  • Kann O., Kovacs R., Njunting M., Behrens C. J., Otahal J., Lehmann T. N., Gabriel S. and Heinemann U. (2005) Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain 128, 23962407.
  • Kapogiannis D. and Mattson M. P. (2011) Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 10, 187198.
  • Karran E., Mercken M. and De Strooper B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698712.
  • Kasischke K. A., Vishwasrao H. D., Fisher P. J., Zipfel W. R. and Webb W. W. (2004) Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 305, 99103.
  • Klaidman L. K., Leung A. C. and Adams J. D., Jr (1995) High-performance liquid chromatography analysis of oxidized and reduced pyridine dinucleotides in specific brain regions. Anal. Biochem. 228, 312317.
  • Koffie R. M., Hyman B. T. and Spires-Jones T. L. (2011) Alzheimer's disease: synapses gone cold. Mol. Neurodegener. 6, 63.
  • Koga Y., Povalko N., Katayama K., Kakimoto N., Matsuishi T., Naito E. and Tanaka M. (2011) Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev. 34, 8791.
  • Komaki H., Nishigaki Y., Fuku N., Hosoya H., Murayama K., Ohtake A., Goto Y., Wakamoto H., Koga Y. and Tanaka M. (2010) Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. Biochim. Biophys. Acta 1800, 313315.
  • Kudin A. P., Zsurka G., Elger C. E. and Kunz W. S. (2009) Mitochondrial involvement in temporal lobe epilepsy. Exp. Neurol. 218, 326332.
  • Kurz A. and Perneczky R. (2011) Amyloid clearance as a treatment target against Alzheimer's disease. J. Alzheimers Dis. 24(Suppl 2), 6173.
  • Manczak M., Anekonda T. S., Henson E., Park B. S., Quinn J. and Reddy P. H. (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15, 14371449.
  • Mark R. J., Pang Z., Geddes J. W., Uchida K. and Mattson M. P. (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17, 10461054.
  • Miners J. S., Barua N., Kehoe P. G., Gill S. and Love S. (2011) Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944959.
  • Minkeviciene R., Ihalainen J., Malm T., et al. (2008) Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 105, 584594.
  • Minkeviciene R., Rheims S., Dobszay M. B., et al. (2009) Fibrillar β-amyloid-induced hyperexcitability of cortical and hippocampal neurons triggers progressive epilepsy. J. Neurosci. 29, 34533462.
  • Mosconi L., Mistur R., Switalski R., et al. (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811822.
  • Murray I. V., Proza J. F., Sohrabji F. and Lawler J. M. (2011) Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. (Maywood) 236, 772782.
  • Noebels J. (2011) A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52(Suppl 1), 3946.
  • O'Connor T., Sadleir K. R., Maus E., et al. (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 9881009.
  • Obel L. F., Muller M. S., Walls A. B., Sickmann H. M., Bak L. K., Waagepetersen H. S. and Schousboe A. (2012) Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Front. Neuroenergetics 4, 3.
  • Oz G., Kumar A., Rao J. P., Kodl C. T., Chow L., Eberly L. E. and Seaquist E. R. (2009) Human brain glycogen metabolism during and after hypoglycemia. Diabetes 58, 19781985.
  • Oz G., Seaquist E. R., Kumar A., Criego A. B., Benedict L. E., Rao J. P., Henry P. G., Van De Moortele P. F. and Gruetter R. (2007) Human brain glycogen content and metabolism: implications on its role in brain energy metabolism. Am. J. Physiol. Endocrinol. Metab. 292, E946E951.
  • Palop J. J., Chin J., Roberson E. D., et al. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697711.
  • Palop J. J. and Mucke L. (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66, 435440.
  • Pan J. W., Williamson A., Cavus I., Hetherington H. P., Zaveri H., Petroff O. A. and Spencer D. D. (2008) Neurometabolism in human epilepsy. Epilepsia 49(Suppl 3), 3141.
  • Patterson C., Feightner J., Garcia A. and MacKnight C. (2007) General risk factors for dementia: a systematic evidence review. Alzheimers Dement. 3, 341347.
  • Pellerin L. and Magistretti P. J. (2011) Sweet sixteen for ANLS. J. Cereb. Blood Flow Metab. 32, 11521166.
  • Pitler T. A. and Landfield P. W. (1987) Postsynaptic membrane shifts during frequency potentiation of the hippocampal EPSP. J. Neurophysiol. 58, 866882.
  • Prapong T., Buss J., Hsu W. H., Heine P., West Greenlee H. and Uemura E. (2002) Amyloid beta-peptide decreases neuronal glucose uptake despite causing increase in GLUT3 mRNA transcription and GLUT3 translocation to the plasma membrane. Exp. Neurol. 174, 253258.
  • Quiroz Y. T., Budson A. E., Celone K., Ruiz A., Newmark R., Castrillon G., Lopera F. and Stern C. E. (2012) Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann. Neurol. 68, 865875.
  • Rheims S., Holmgren C. D., Chazal G., Mulder J., Harkany T., Zilberter T. and Zilberter Y. (2009) GABA action in immature neocortical neurons directly depends on the availability of ketone bodies. J. Neurochem. 110, 13301338.
  • Roberson E. D., Halabisky B., Yoo J. W., et al. (2011) Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700711.
  • Sah R. and Schwartz-Bloom R. D. (1999) Optical imaging reveals elevated intracellular chloride in hippocampal pyramidal neurons after oxidative stress. J. Neurosci. 19, 92099217.
  • Saxena U. (2010) Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Expert Opin. Ther. Targets 14, 12731277.
  • Saxena U. (2011) Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int. J. Physiol. Pathophysiol. Pharmacol. 3, 133139.
  • Selkoe D. J. (2011) Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 3, 116.
  • Shemer I., Holmgren C., Min R., et al. (2006) Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 23, 20352047.
  • Shetty P. K., Galeffi F. and Turner D. A. (2012a) Cellular Links between Neuronal Activity and Energy Homeostasis. Front. Pharmacol. 3, 43.
  • Shetty P. K., Sadgrove M. P., Galeffi F. and Turner D. A. (2012b) Pyruvate incubation enhances glycogen stores and sustains neuronal function during subsequent glucose deprivation. Neurobiol. Dis. 45, 177187.
  • Shuttleworth C. W. (2010) Use of NAD(P)H and flavoprotein autofluorescence transients to probe neuron and astrocyte responses to synaptic activation. Neurochem. Int. 56, 379386.
  • Sickmann H. M., Walls A. B., Schousboe A., Bouman S. D. and Waagepetersen H. S. (2009) Functional significance of brain glycogen in sustaining glutamatergic neurotransmission. J. Neurochem. 109(Suppl 1), 8086.
  • Small S. A. and Duff K. (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60, 534542.
  • Stampfer M. J. (2006) Cardiovascular disease and Alzheimer's disease: common links. J. Intern. Med. 260, 211223.
  • Tillement L., Lecanu L. and Papadopoulos V. (2011) Alzheimer's disease: effects of beta-amyloid on mitochondria. Mitochondrion 11, 1321.
  • Tsai Y. C., Chou Y. C., Wu A. B., Hu C. M., Chen C. Y., Chen F. A. and Lee J. A. (2006) Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. Life Sci. 78, 13851391.
  • Vassar R. and Kandalepas P. C. (2011) The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res. Ther. 3, 20.
  • Velliquette R. A., O'Connor T. and Vassar R. (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25, 1087410883.
  • Vernia P., Monteleone G., Grandinetti G., Villotti G., Di Giulio E., Frieri G., Marcheggiano A., Pallone F., Caprilli R. and Torsoli A. (2000) Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig. Dis. Sci. 45, 976981.
  • Verret L., Mann E. O., Hang G. B., et al. (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708721.
  • Waldbaum S. and Patel M. (2010) Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 88, 2345.
  • Wang T. A., Yu Y. V., Govindaiah G., Ye X., Artinian L., Coleman T. P., Sweedler J. V., Cox C. L. and Gillette M. U. (2012a) Circadian rhythm of redox state regulates excitability in suprachiasmatic nucleus neurons. Science 337, 839842.
  • Wang Y. C., Yang J. J. and Huang R. C. (2012b) Intracellular Na(+) and metabolic modulation of Na/K pump and excitability in the rat suprachiasmatic nucleus neurons. J. Neurophysiol. 108, 20242032.
  • Yao J., Irwin R. W., Zhao L., Nilsen J., Hamilton R. T. and Brinton R. D. (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106, 1467014675.
  • Zilberter Y., Zilberter T. and Bregestovski P. (2010) Neuronal activity in vitro and the in vivo reality: the role of energy homeostasis. Trends Pharmacol. Sci. 31, 394401.